Pharmaceutical care, European developments in concepts, implementation, teaching, and research: A review

Pharmacy World and Science

Volumn 26, Issue 6, 2004, Pages 303-311

  Van Mil, J W Foppe ^a   Schulz, Martin ^b   Tromp, Th F J ^c  

^a Fed Union Ger Associations P ^*  (Netherlands)

^b ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^c Qual Inst for Pharmaceutical Care   (Netherlands)

Author keywords

Europe; Implementation; Pharmaceutical care; Pharmaceutical care research; Pharmacy education; Pharmacy practice; Pharmacy services

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL PRACTICE; COUNSELING; CURRICULUM; DECISION MAKING; EUROPE; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; OUTCOMES RESEARCH; PHARMACEUTICAL CARE; PHARMACIST; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RESPONSIBILITY; REVIEW; SCIENCE; SKILL; TEACHING;

EDUCATION, PHARMACY; EUROPE; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; RESEARCH;

EID: 12544249868     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-004-2849-0     Document Type: Review

References (102)

1. Mikael RL, Brown TR, Lazarus HL, Vinson MC. Quality of pharmaceutical care in hospitals. Am J Hosp Pharm 1975; 32: 567-74.
2. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43.
3. Anonymous. A pharmacy Pioneer. Int Pharm J 1997; 11 (3): 69.
4. Cipolle RJ, Strand LM, Morley PC. A new professional practice. Pharmaceutical care practice. New York: McGraw-Hill, 1998, ISBN 0-07-012046-3. 13.
5. Hepler CD. Pharmaceutical Care. Pharm World Sci 1996; 18: 233-6.
6. Hepler CD. Regulating for outcomes as a systems response to the problem of drug-related morbidity. J Am Pharm Assoc (Wash) 2001; 41: 108-15.
7. Morris CJ, Cantrill JA, Hepler CD, Noyce PR. Preventing drug-related morbidity-determining valid indicators. Int J Qual Health Care 2002; 14(3): 183-98.
8. Anonymous. Pharmaceutical care, towards an international understanding? Pharm J 1999; 263(7063): 464.
9. Hepler CD, Angaran D. The nature of caring. In: Knowlton CH, Penna RP, editors. Pharmaceutical care. New York: Chapman & Hall, 1996.
10. Van Mil JWF, McElnay JC, de Jong-van den Berg LTW, Tromp ThFJ. The challenges of defining pharmaceutical care on an international level. Int J Pharm Practice 1999; 7: 202-8.
11. Barber N. Pharmaceutical care and medicines management-Is there a difference. Pharm World Sci 2001; 23: 210-1.
12. Hepler CD, Grainger-Rousseau TJ. Pharmaceutical care versus traditional drug treatment; is there a difference? Drugs 1995; 49: 1-10.
13. Hepler CD. The Pharmacist in the medication use process (an Introduction to pharmaceutical care). In: Hepler CD, editor. Pharmaceutical care in community practice. Proceedings of the Section of Community Pharmacists. World Congress of Pharmacy and Pharmaceutical Sciences, 1993, Tokyo, Japan. Hillerod, Denmark: FIP, 1995.
14. Anonymous. ASHP guidelines in pharmacist-conducted patient education and counseling. Am J Health Syst Pharm 1997; 54: 431-4.
15. Hughes CM, McElnay JC, Fleming GF. Benefits and risks of self medication. Drug Safety 2001; 24: 1027-37.
16. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001; 41(2): 192-9.
17. Patel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem. Pharmacotherapy 2002; 22: 915-23.
18. Marco JL, Boscá B, San Martín D, Borrás J, Díez Martínez A. Ingresos hospitalarios por problemas relacionados con la medicación en el hospital general de requena (1997-2000). [Drug-related problem hospitalization in the Requena general hospital.] Pharm Care Esp 2002; 4: 286-99.
19. Hallas J. Drug related hospital admissions in subspecialities of internal medicine [Dissertation]. Copenhagen: Lageforeningens Forlag, 1995.
20. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54.
21. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm. 1997; 54: 554-8.
22. Stig Haugbølle L, Westh Sørensen E, Herborg Henriksen H. Medication- and illness-related factual knowledge, perceptions and behaviour in angina pectoris patients. Pat Educ Couns 2002; 47: 282-9.
23. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PRS, Downie G, Seymour DG. Pharmacist-led medication review in patients over 65: a randomized controlled trial in primary care. Age Ageing 2001; 30: 205-11.
24. Kansanaho H, Isonen-Sjolund N, Pietila K, Airaksinen M, Isonen T. Patient counselling profile in a Finnish pharmacy. Patient Educ Couns 2002; 47: 77-82.
25. Bell HM, McElnay JC, Hughes CM. Societal perspectives on the role of the community pharmacist and community-based pharmaceutical services. J Soc Admin Pharm 2000; 17: 119-28.
26. Hawksworth GM, Corlett AJ, Wright DJ, Chrystyn H. Clinical pharmacy interventions by community pharmacists during the dispensing process. Br J Clin Pharmacol 1999; 47: 695-700.
27. van Mil JWF, Dudok van Heel MC, Boersma M, Tromp TFJ. Interventions and documentation for drug-related problems in Dutch community pharmacies. Am J Health Syst Pharm 2001; 58: 1428-31.
28. Buurma H, de Smet PAGM, van den Hoff OP, Egberts ACG. Nature, frequency and determinants of prescription modifications in Dutch community pharmacies. Br J Clin Pharmacol 2001; 52: 85-91.
29. Kleir NM, van Mil JWF, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care. Pharm World Sci 2004; 26: 125-8.
30. Roughead L, Semple S, Vitry A. The value proposition of pharmacist professional services in the community setting. A systematic review of the literature 1990-2002. www.guild.org/ public/researchdocs/reportvalueservices.pdf (6 February 2004).
31. Anderson C, Blenkinsopp A, Armstrong M. The contribution of pharmacy to improving the public's health. Report 1, Evidence from the peer-reviewed literature. Pharmacy Health Link and Royal Pharmaceutical Society of Great Britain, 2003. ISBN 0-9538505-1-X. www.pharmacyhealthlink.org.uk.
32. Anderson C, Blenkinsopp A, Armstrong M. The contribution of pharmacy to improving the public's health. Report 2, Evidence from the UK non peer-reviewed literature. Pharmacy Health Link and Royal Pharmaceutical Society of Great Britain, 2003. ISBN 0-9538505-5-2. www.pharmacyhealthlink.org.uk.
33. Søndergaard B, Herborg H, Knudsen MS, Nielsen HP, Tomsen DV. The Danish community pharmacy database. In: Proceedings, Workshop Programs and Abstracts, Social Pharmacy Workshop, Malta, 19-23 July 2004, p. 4.02. Malta: College of Pharmacy Practice, 2004. ISBN 9993268100.
34. Kennie NR, Schuster BG, Einarson TR. Critical analysis of the pharmaceutical care research literature. Ann Pharmacother 1998; 32(1): 17-26.
35. Plumridge RJ, Wojnar-Horton RE. A Review of the pharmacoeconomics of pharmaceutical care. PharmacoEconomics 1998; 14(2): 175-89.
36. McLean W. Pharmaceutical care evaluated: the value of your services. Can Pharm J 1998; 131: 34-40.
37. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Library. Cochrane Collaboration. Cochrane Effective Practice and Organisation of Care Group. 2001.
38. Leemans L, Veroeveren L, Buelens J, Hendrickx C, Keyenberg W, Niesten F et al. Frequency and trends of interventions on prescriptions in Flemish pharmacies. Pharm World Sci 2003; 25: 65-9.
39. Chamba G, Bauguil G, Galiezot J. The role of the French community pharmacist in drug dispensing. Pharm World Sci 1999; 21: 142-3.
40. Schaefer M, Kresser J. Pharmazeutische Betreuung vermeidet Schäden. [Pharmaceutical care prevents damage.] Pharm Ztg 1998; 143: 4446-54.
41. Saanum DT, Mellbye KS. The prescription as an aid for communication between physicians and pharmacists. A study of errors and insufficient information on prescriptions. Tidsskr Nor Laegeforen 1996; 116: 2325-9.
42. Tully MP, Seston EM. The impact of pharmacists providing prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother 2000; 34: 1320-31.
43. Westerlund T, Almarsdóttir AB, Melander A. Drug-related problems and pharmacy interventions in community practice, Int J Pharm Practice 1999; 7: 40-50.
44. Fernández-Llimós F, Faus MJ. Resultados del Programa Dáder de Seguimiento Farmacoterapéutico del paciente en España. [Results of the Dáder Program of Pharmaceutical Care in Spain.] El Farmacéutico 2002; 290: 83-8.
45. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10(4): 199-205.
46. Kocken GA. Medication discussion groups in the Netherlands: five years of experience. Med Educ 1999; 33: 390-3.
47. Corbett J. Provision of prescribing advice by community pharmacists. Pharm J 1995; 255: 555-7.
48. de Vries CS. Collaboration in healthcare [Dissertation] University of Groningen, 1998. ISBN 90-367-0978-4.
49. van Eijk MEC. Effects of outreach strategies on quality of pharmacotherapy [Dissertation] University of Utrecht, 2000. ISBN 90-5054-155-0.
50. Denig P, Wahlstrom R, De Saintonge MC, Haaijer-Ruskamp F. The value of clinical judgement analysis for improving the quality of doctors' prescribing decisions. Med Educ 2002: 36(8): 770-80.
51. Sondergaard B, Thorleifsson S, Herborg H, Frøkjaer B, Hepler CD, Ersboll BK. Kvalitetssikring af astmapatienters laegemiddelbehandling, Sundhedsøkonomisk analyse. [Quality assurance of drug therapy for patients with asthma. Health economic analysis.] Ugeskr Laeger 2000; 162(4): 480-6.
52. Herborg H, Soendergaard B, Froekjaer B, Fonnesbaek L, Jorgensen T, Hepler CD et al. Improving drug therapy for patients with asthma-part 1: patient outcomes. J Am Pharm Assoc (Wash.) 2001; 4(4): 539-50.
53. Herborg H, Soendergaard B, Jorgensen T, Fonnesbaek L, Hepler CD, Holst H et al. Improving drug therapy for patients with asthma-part 2: Use of antiasthma medications. J Am Pharm Assoc (Wash.) 2001; 41(4): 551-9.
54. Närhi U. Implementing the philosophy of pharmaceutical care into community pharmacy services-experiences with asthma patients in Finland [Dissertation] Kuopion Yliopisto, Kuopio 2001. ISBN 951-781-152-7.
55. Schulz M, Verheyen F, Mühlig S, Müller JM, Mühlbauer K, Knop-Schneikert E et al. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol 2001; 41(6): 668-76.
56. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001; 21: 1196-203.
57. van Mil JWF. Results of pharmaceutical care in asthma, the TOM study. In: pharmaceutical care, the future of pharmacy [Dissertation] Groningen 1999. ISBN 90-9013367-4.
58. Granger-Rousseau TJ, McElnay JC. A model for community pharmacist involvement with general practitioners in the management of asthma patients. J Appl Ther 1997; 1: 145-61.
59. Jácome JA, García AI. Estudio prospectivo sobre el impacto de un servicio de atencíon farmacéutica comunitaria en personas asmáticos. [Prospective study about the impact of a community pharmaceutical care service in patients with asthma.] Rev Esp Salud Pública 2003; 77: 393-403.
60. Garcão JA, Cabrita J. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm Assoc 2002; 42: 858-64.
61. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy 1999; 19(7): 860-9.
62. Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E et al A. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18(1): 63-77.
63. Bonal JF. Clinical pharmacy in inpatient care. Pharmacotherapy 2000; 20 (10 Pt 2): 264S-72S.
64. Tromp ThFJ (Ed.). Continuing professional development. Improving patient outcomes by pharmacists' interventions. Outcomes in day-to-day practice. Proceedings of the Community Pharmacy Section. FIP, Barcelona, Spain, September 9-10, 1999.
65. Weinberger M, Murray MD, Marrero D, Brewer N, Lykens M, Harris LE et al. Effectiveness of pharmacist care for patients with reactive airways disease; a randomized controlled trial. JAMA 2002: 288(13): 1594-1602.
66. van Mil JWF. Is Hawthorne bothering pharmaceutical care research? [Editorial]. Pharm World Sci 2003; 25: 37.
67. Kozma CM, Reeder CE, Schulz RM. Economic, clinical and humanistic outcomes: a planning model for Pharmacoeconomic research. Clin Ther 1993; 15(6): 1121-32.
68. Tully MP, Cantrill JA. Subjective outcome measurement-a primer. Pharm World Sci 1999; 21(3): 101-9.
69. van Mil JWF, editor. Proceedings of the International Working Conference on Outcomes Measurement in Pharmaceutical Care. Hillerod, Denmark: PCNE, 1999.
70. Schulz M, editor. Proceedings of the 2nd International Working Conference on Quality Issues in Pharmaceutical Care Research. Hillerød, Denmark: PCNE, 2001. http://www.pcne.org/ proceedings2001.htm (6 February 2004).
71. Horne R, Weinman J, Hankins M. The beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psych Health 1999; 14: 1-24.
72. Mobach MP. From the laboratory to pharmaceutical care research. Pharm World Sci 2001; 23: 205-9.
73. Rossing C. The practice of pharmaceutical care in Denmark-a quantatative approach [Dissertation]. The Danish University of Pharmaceutical Sciences, 2003. ISBN 87-983302-3-3.
74. van Mil JWF, de Boer WO, Tromp ThFJ. European barriers to the implementation of pharmaceutical care. Int J Pharm Practice 2001; 9: 163-7.
75. Bell HM, McElnay JC, Hughes CM, Woods A. Provision of pharmaceutical care by community pharmacists in Northern Ireland. Am J Health Syst Pharm 1998; 55: 2009-13.
76. Bell HM, McElnay JC, Hughes CM. A qualitative investigation of the attitudes and opinions of community pharmacists to pharmaceutical care. J Soc Adm Pharm 1998; 15: 284-95.
77. Rossing C, Holme Hansen E, Krass I. Barriers and facilitators in pharmaceutical care: perceptions and experiences among Danish community pharmacists. J Soc Adm Pharm 2001; 19: 55-64.
78. Crealey GE, Sturgess IK, McElnay JC, Hughes CM. Pharmaceutical care programmes for the elderly: economic issues. Pharmacoeconomics 2003; 21: 455-65.
79. Muijrers PEM, Knotnerus JA, Sijbrandij J, Janknegt R, Grol RPTM. Changing relationships: attitudes and opinions of general practitioners and pharmacists regarding the role of community pharmacists. Pharm World Sci. 2003; 25: 235-41.
80. Reebye RN, Avery AJ, Bissell P, Van Weel C. The issue of territoriality between pharmacists and physicians in primary care. Int J Pharm Practice 2002; 10(2): 69-75.
81. Kinget R. Put community pharmacy on a brand new track. Int Pharm J 2000; 14: 4-7.
82. Tromp ThF, editor. Report of the Task Force for Implementing Pharmaceutical Care. Groningen/Kampen: European Association of Faculties of Pharmacy, 1999. Kampen, The Netherlands: Quality Institute for Pharmaceutical Care.
83. Sørensen EW, Mount JK, Christensen ST. The concept of social pharmacy. Chronic III 2003; 7(summer): 12-5.
84. Himstedt S, Kirchhoff G. Hausapotheke. Pharmazeutische dienstleistung für die patienten. [Family pharmacy. Pharmaceutical services for patients.] Pharm Ztg 2004; 149(19): 1522-31.
85. van Mil JWF, Frøkjaer BF, Tromp ThFJ. Changing a profession, influencing community pharmacy. Pharm World Sci 2004; 26: 129-32.
86. Haugbolle LS, Sorensen EW, Henriksen HH. Medication- and illness-related factual knowledge, perceptions and behaviour in angina pectoris patients. Patient Educ Couns 2002; 47(4): 281-9.
87. Sørensen EW, Haugbolle LS, Herborg H, Lorenzen L. Participatory action research as an implementation strategy [Poster Abstract]. PCNE Working Conference: Pharmaceutical Care Research - the Next Generation. Hillerød, Denmark: PCNE, 2003.
88. De Almeida Neto AC. The pseudo-patron: a real education. Aust J Pharm 2003; 84: 314-5.
89. Van Mil F. Hoe doen we het? [How are we doing?] [Editorial]. Pharm Weekbl 2003; 138: 865
90. Roberts AS, Hopp T, Sørensen EW, Benrimoj SI, Chen TF, Herborg H, Williams K, Aslani P. Understanding practice change in community pharmacy: a qualitative research instrument based on organisational theory. Pharm World Sci 2003; 25: 227-34.
91. Dessing RP, Flameling J. Ethics in pharmacy: a new definition of responsibility. Pharm World Sci 2003; 25: 3-10.
92. MacKeigan LD. Alternative reimbursement systems in community pharmacy: structure, perceptions and performance. J Res Pharm Econ 2001; 11(2): 53-74.
93. Benrimoj SI, Langford JH, Berry G, Collins D, Lauchlan R, Stewart K et al. Impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance. Pharmacoeconomics 2000; 18(5): 459-68.
94. A Vision for Pharmacy in the new NHS. Department of Health, London, UK, July 2003. Point 3.11, page 12. http:// www.doh.gov.uk/pharmacyvision/ visionforpharmacy (9 February 2004).
95. Herborg H. The pharmaceutical care concept- Personal views with a focus on development projects in Denmark. Int Pharm J 1995; 9: 148-9.
96. Herborg H, Fonnesbaek L, Frøkjaer B, Søndergaard B. The councelling pharmacy [Abstract and poster]. Abstract no CPSP-235. World Congress of Pharmacy and Pharmaceutical Sciences, 62nd Congress of Fip, Nice, France, 2002.
97. Haugbolle LS, Sorensen EW, Gundersen B, Petersen KH, Lorentzen L. Basing pharmacy counselling on the perspective of the angina pectoris patient. Pharm World Sci 2002; 24: 71-8.
98. Westerlund T, Allenbeck P, Marklund B, Andersson IL, Brånstad JO, Sjöblom M. Evaluation of a model for counseling patients with dyspepsia in Swedish community pharmacies. Am J Health-Syst Pharm 2003; 60: 1336-41.
99. Silcock J, Raynor DK, Petty D. The organisation and development of primary care pharmacy in the United Kingdom. Health Policy 2004; 67: 207-14.
100. FIP statement of professional standards: Pharmaceutical care. http://www.fip.org/pdf/pharmcare.pdf (5 February 2004).
101. Council of Europe, Committee of Ministers. Resolution ResAP(2001)2 concerning the pharmacist's role in the framework of health security. Adopted by the Committee of Ministers on 21 March 2001 at the 746th meeting of the Ministers' Deputies. http:// cm.coe.int/ta/res/resAP/2001/2001xp2.htm (6 February 2004).
102. Hepler CD. Pharmaceutical care and specialty practice. Pharmacotherapy 1993; 13: 64S-9S.